References:
1. McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma
cell neoplasms. En Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA,
Stein H, et al. editores. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Lyon FWHOC of T of H and LT 2017.,
Swerdlow SH, Campo E, et al. WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Lyon, France .; 2017.
doi:10.1017/CBO9781107415324.004
2. Nalesnik MA. Plasma cell tumors In transplant patients. Blood .
2013;121(8):1247-1249. doi:10.1182/blood-2013-01-475947
3. Opelz G, Henderson R. Incidence of non-hodgkin lymphoma in kidney and
heart transplant recipients. Lancet .
1993;342(8886-8887):1514-1516. doi:10.1016/S0140-6736(05)80084-4
4. Opelz G, Döhler B. Lymphomas after Solid Organ Transplantation: A
Collaborative Transplant Study Report. Am J Transplant .
2004;4(2):222-230. doi:10.1046/j.1600-6143.2003.00325.x
5. Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B. Posttransplant
lymphoproliferative disease after pediatric solid organ transplantation.Clin Dev Immunol . 2013;2013. doi:10.1155/2013/814973
6. West SC, Friedland-Little JM, Schowengerdt KO, et al.
Characteristics, risks, and outcomes of post-transplant
lymphoproliferative disease >3 years after pediatric heart
transplant: A multicenter analysis. Clin Transplant .
2019;33(5):1-8. doi:10.1111/ctr.13521
7. Perry AM, Aoun P, Coulter DW, Sanger WG, Grant WJ, Coccia PF. Early
onset, EBV- PTLD in pediatric liver-small bowel transplantation
recipients: A spectrum of plasma cell neoplasms with favorable
prognosis. Blood . 2013;121(8):1377-1383.
doi:10.1182/blood-2012-06-438549
8. Short SRP, Cook SL, Kim AS, Lamour JM, Lowe EJ, Petersen WC.
Plasmacytoma-like posttransplant lymphoproliferative disorder in a
pediatric heart transplant recipient. J Pediatr Hematol Oncol .
2016;38(2):e71-e74. doi:10.1097/MPH.0000000000000501
9. Xue L, Zuppan C, Wang T, Kheradpour A, Rowsell EH, Wang J. Plasma
Cell Myeloma Type Posttransplant Lymphoproliferative Disorder in an
18-Month-Old Heart Transplant Recipient: Case Report and Review of the
Literature. J Pediatr Hematol Oncol . 2020;42(3):e170-e173.
doi:10.1097/MPH.0000000000001510
10. Yang CH, Gombar S, Twist CJ, Gratzinger D, Esquivel CO, Lau AH.
hyperviscosity syndrome in a child after liver transplant.
2017;64(6):2250-2252. doi:10.1002/hep.28657.Plasmacytoid
11. Epperly R, Ozolek J, Soltys K, Cohen D, Goyal R, Friehling E.
Treatment of pediatric plasma cell myeloma type post-transplant
lymphoproliferative disorder with modern risk-directed therapy.Pediatr Blood Cancer . 2018;65(10):4-7. doi:10.1002/pbc.27283
12. Plant AS, Venick RS, Farmer DG, Upadhyay S, Said J, Kempert P.
Plasmacytoma-like post-transplant lymphoproliferative disorder seen in
pediatric combined liver and intestinal transplant recipients.Pediatr Blood Cancer . 2013. doi:10.1002/pbc.24632
13. Tcheng WY, Said J, Hall T, Al-Akash S, Malogolowkin M, Feig SA.
Post-transplant multiple myeloma in a pediatric renal transplant
patient. Pediatr Blood Cancer . 2006. doi:10.1002/pbc.20482
14. Zuckerman WA, Zeevi A, Mason KL, et al. Study rationale, design, and
pretransplantation alloantibody status: A first report of Clinical
Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric
heart transplantation. Am J Transplant . 2018.
doi:10.1111/ajt.14695
15. Barth Syndrome - NORD (National Organization for Rare Disorders).
https://rarediseases.org/rare-diseases/barth-syndrome/.
16. Galera P, Flavin R, Savage NM, et al. Epstein-Barr Virus-negative
Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant
Lymphoproliferative Disorder. Am J Surg Pathol .
2020;44(10):1340-1352. doi:10.1097/PAS.0000000000001514
17. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib,
cyclophosphamide and dexamethasone in newly diagnosed and relapsed
multiple myeloma: LYRA study. Br J Haematol . 2019;185(3):492-502.
doi:10.1111/bjh.15806
18. Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine and
rituximab in splenic marginal zone lymphoma: results from the phase II
BRISMA/IELSG36 study. Br J Haematol . 2018;183(5):755-765.
doi:10.1111/bjh.15641
19. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis,
risk-stratification, and management. Am J Hematol .
2018;93(8):1091-1110. doi:10.1002/ajh.25117
20. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide
and Dexamethasone for Untreated Myeloma. N Engl J Med . 2019.
doi:10.1056/nejmoa1817249